Showing results (101-110 of 443) with videos related to
Sort By:
Pageof 45
Clinical Colorectal Cancer|July 27, 2019
Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal CancerAdam Cerise, Tapan K Bera, Xiufen Liu, et al.The Journal of Biological Chemistry|July 13, 2012
Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insightsJichun Ma, Wai Kwan Tang, Lothar Esser, et al.Molecular Cancer Therapeutics|May 20, 2016
Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant ImmunotoxinsPrince Awuah, Tapan K Bera, Messan Folivi, et al.Communications Biology|December 2, 2020
Multiple proteases are involved in mesothelin shedding by cancer cellsXiufen Liu, Alexander Chan, Chin-Hsien Tai, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicitySookhee Bang, Satoshi Nagata, Masanori Onda, et al.Mabs|April 26, 2012
Targeting malignant B cells with an immunotoxin against ROR1Sivasubramanian Baskar, Adrian Wiestner, Wyndham H Wilson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage displayGiuliana Salvatore, Richard Beers, Inger Margulies, et al.International Journal of Medical Microbiology : IJMM|May 20, 2004
Recombinant immunotoxins for treating cancerDavid J FitzGerald, Robert Kreitman, Wyndham Wilson, et al.Blood|March 1, 2014
Immunotoxins for leukemiaAlan S Wayne, David J Fitzgerald, Robert J Kreitman, et al.Cancer Research|October 15, 2011
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugatesDavid J FitzGerald, Alan S Wayne, Robert J Kreitman, et al.Pageof 45